We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The US unit of Indian drugmaker Lupin has agreed a marketing partnership deal
with Cornerstone BioPharma Inc to promote its Suprax (cefixime) anti-infective.
India-based pharmaceuticals producer Zydus Cadila has reported a
29% year-on-year increase in net profit for the third quarter ended December
2004, to INR395mn (US$9.03mn).
According to international reports, leading Japanese drugmaker Takeda
is expected to exceed its own profit target this year, despite weak sales in
the US.
Japanese company Meiji Seika Kaisha is to boost its operations in China, opening
a new JPY3bn (US$29mn) joint venture antibiotic products factory in April.
Indian generics producer Ranbaxy has claimed that it will not proceed
with its plans to launch a generic version of Pfizer's blockbuster cholesterol
treatment Lipitor (atorvastatin) until related legal issues are resolved.
Israeli drugmaker Teva has claimed that its global sales of Copaxone,
an ethical injectable therapy for muscular degenerative disorder multiple schlerosis,
reached record levels of US$261mn in the fourth quarter of 2004.
Leading South African generics maker Aspen Pharmacare has
received tentative approval for a combination antiretroviral under the US government's
PEPFAR initiative.